Thor Halfdanarson/mayoclinic.org
May 20, 2025, 14:45
Thor Halfdanarson: Lot to unpack from the excellent NORDIC NEC 2 Study
Thor Halfdanarson, Medical Oncologist at the Mayo Clinic, shared a post on X about recent article Halfdan Sorbye and colleagues authored:
“Lot to unpack from the excellent NORDIC NEC2.
– ORR: 31% for NEC (mostly plat/eto) – this is NOT SCLC
– ORR: 27% for G3 NETs (mostly TMZ-based)
– Immediate progression: 41% of NECs, 21% G3 NETs
– PFS: 3.4 m NEC; 7.4 G3 NETNECs are really bad cancers!”
Title: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study
Authors: Halfdan Sorbye, Geir Olav Hjortland, Lene Weber Vestermark, Morten Ladekarl, Johanna Svensson, Anna Sundlöv, Eva Tiensuu Janson, Herish Garresori, Eva Hofsli, Christian Kersten, Hege Elvebakken, Per Pfeiffer, Siren Morken, Jorg Assmus, Inger Marie Bowitz Lothe, Elizaveta Tabaksblat, Ulrich Knigge, Anne Couvelard, Aurel Perren, Seppo W. Langer
Read Full Article.
More posts featuring Thor Halfdanarson on OncoDaily.
Anna Sundlöv
Anne Couvelard
Aurel Perren
cancer
Christian Kersten
Elizaveta Tabaksblat
Eva Hofsli
Eva Tiensuu Janson
Geir Olav Hjortland
Halfdan Sorbye
Hege Elvebakken
Herish Garresori
Inger Marie Bowitz Lothe
Johanna Svensson
Jorg Assmus
Lene Weber Vestermark
Morten Ladekarl
OncoDaily
Oncology
Per Pfeiffer
Seppo W. Langer
Siren Morken
Thor Halfdanarson
Ulrich Knigge
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 19, 2025, 14:29
Jul 19, 2025, 13:48
Jul 19, 2025, 13:42
Jul 19, 2025, 13:28
Jul 19, 2025, 11:05
Jul 19, 2025, 10:29
Jul 19, 2025, 10:12
Jul 19, 2025, 09:55